Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III trial of intravenous efgartigimod for the treatment of immune thrombocytopenia (ITP)

Next Previous
Trial Profile

A Phase III trial of intravenous efgartigimod for the treatment of immune thrombocytopenia (ITP)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efgartigimod (Primary)
  • Indications Idiopathic thrombocytopenic purpura
  • Focus Registrational; Therapeutic Use
  • Acronyms ADVANCE
  • Sponsors argenx

    • Most Recent Events

    • 24 Oct 2019 According to argenx media release, company plans to initiate in the 4Q of 2019
    • 02 Nov 2018 New trial record
    • 25 Oct 2018 According to an Argenx media release, the company plans to initiate this trial in the second half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top